26 Nov, 2024 IPOs in Life Sciences By James Baillieu Fiona McFarlane The amount of capital required to develop and bring a drug to market is significant. It is estimated that it costs US$1-2 billion to...
04 Nov, 2024 Licensing and Collaborations in Life Sciences By James Baillieu Sally Shorthose There is a huge cost of bringing a pharmaceutical product to market, with estimates ranging from US$1-2 billion to take a product from...
28 Oct, 2024 EU Pharmaceutical Reform: Update on the proposed changes to paediatric medicinal product legislation By Phillipus Putter This article is part of our series covering the proposed reforms to the EU pharmaceutical legislation. To view the entire series, click...
18 Oct, 2024 Venture Capital and Venture Debt in Life Sciences By James Baillieu In recent decades, venture capital (VC) has played an increasingly important role in the high-risk and high-reward life sciences sector....
11 Sep, 2024 EU Pharmaceutical Reform: Update on the proposed changes to marketing authorisation procedures By Sally Shorthose Sophie Vo This article is part of our series covering the proposed reforms to the EU pharmaceutical legislation. To view the entire series, click...